Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1993 Oct;67(4):169-73.
doi: 10.1007/BF01695863.

Effect of recombinant human erythropoietin after allogenic bone marrow transplantation

H Link  1 , T Brune, G Hübner, H Diedrich, M Freund, M Stoll, D Peest, W Ebell, C Bettoni, W Oster, et al.
Affiliations
Clinical Trial

Effect of recombinant human erythropoietin after allogenic bone marrow transplantation

H Link et al. Ann Hematol. 1993 Oct.

Abstract

The hematologic effects of recombinant human erythropoietin after allogeneic bone marrow transplantation (BMT) were studied. Nineteen patients received 150 U/kg/day of C127 mouse-cell-derived recombinant human erythropoietin (rHu EPO) as a daily continuous intravenous infusion until hematocrit exceeded 35%. These data were compared with a treatment-matched historical control group of 43 patients. RHu EPO-treated patients recovered erythropoiesis more rapidly and became independent from erythrocyte transfusions after a median of 17 days, which was 7 days earlier than the control patients.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Bone Marrow Transplant. 1992 Dec;10(6):541-6 - PubMed
    1. N Engl J Med. 1990 Jun 14;322(24):1693-9 - PubMed
    1. N Engl J Med. 1989 Oct 26;321(17):1163-8 - PubMed
    1. Am J Hematol. 1991 Jan;36(1):71-2 - PubMed
    1. Blood. 1989 May 15;73(7):1993-8 - PubMed

Publication types

LinkOut - more resources